Repurposing Doxepin to Ameliorate Steatosis and Hyperglycemia by Activating FAM3A Signaling Pathway
- 20 April 2020
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 69 (6), 1126-1139
- https://doi.org/10.2337/db19-1038
Abstract
Mitochondrial protein FAM3A suppresses hepatic gluconeogenesis and lipogenesis. This study aimed to screen drug(s) that activates FAM3A expression and evaluate its effect(s) on hyperglycemia and steatosis. Drug-repurposing methodology predicted that antidepressive drug doxepin was among the drugs that potentially activated FAM3A expression. Doxepin was further validated to stimulate the translocation of transcription factor HNF4α from the cytoplasm into the nucleus, where it promoted FAM3A transcription to enhance ATP synthesis, suppress gluconeogenesis, and reduce lipid deposition in hepatocytes. HNF4α antagonism or FAM3A deficiency blunted doxepin-induced suppression on gluconeogenesis and lipid deposition in hepatocytes. Doxepin administration attenuated hyperglycemia, steatosis, and obesity in obese diabetic mice with upregulated FAM3A expression in liver and brown adipose tissues (BAT). Notably, doxepin failed to correct dysregulated glucose and lipid metabolism in FAM3A-deficient mice fed on high-fat diet. Doxepin’s effects on ATP production, Akt activation, gluconeogenesis, and lipogenesis repression were also blunted in FAM3A-deficient mouse livers. In conclusion, FAM3A is a therapeutic target for diabetes and steatosis. Antidepressive drug doxepin activates FAM3A signaling pathways in liver and BAT to improve hyperglycemia and steatosis of obese diabetic mice. Doxepin might be preferentially recommended as an antidepressive drug in potential treatment of patients with diabetes complicated with depression.Keywords
Funding Information
- National Key Research Program of China (2017YFC0909600/2016YFC0903000)
- Natural Science Foundation of China (81670748/81471035/81322011/81670462/81422006)
- Beijing Natural Science Foundation (7171006)
This publication has 51 references indexed in Scilit:
- FAM3A is a target gene of peroxisome proliferator-activated receptor gammaBiochimica et Biophysica Acta (BBA) - General Subjects, 2013
- Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosisNature Reviews Gastroenterology & Hepatology, 2013
- Economic aspects of the association between diabetes and depression: A systematic reviewJournal of Affective Disorders, 2012
- HNF4α Antagonists Discovered by a High-Throughput Screen for Modulators of the Human Insulin PromoterCell Chemical Biology, 2012
- Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adultsDiabetologia, 2011
- Hepatic Hepatocyte Nuclear Factor 4α Is Essential for Maintaining Triglyceride and Cholesterol HomeostasisArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Low-Dose DoxepinCNS Drugs, 2010
- Effect of Race/Ethnicity and Persistent Recognition of Depression on Mortality in Elderly Men With Type 2 Diabetes and DepressionDiabetes Care, 2008
- Emotional problems during weight reduction: Advantages of a combined behavior therapy and antidepressive drug therapy for obesityJournal of Behavior Therapy and Experimental Psychiatry, 1985
- Second Generation Antidepressants: A Comparative ReviewThe Journal of Clinical Pharmacology, 1985